Oxford PharmaGenesis and CISCRP strengthen awareness of need for patient diversity

01 June 2021

Share this page

Share this page on LinkedIn

Oxford PharmaGenesis is helping to raise public awareness of the importance of patient diversity in clinical trials through a campaign partnership with the non-profit organization Center for Information and Study on Clinical Research Participation (CISCRP).

Running throughout Spring 2021, the CISCRP Patient Diversity media campaign offers information and resources to minority communities, emphasizing how patient diversity in clinical trials helps scientists to discover treatments that are effective for everyone.

Oxford PharmaGenesis backed the biannual educational initiative when it launched in October last year and continues this support into 2021, in line with the healthcare communications company’s ongoing commitment to equality, diversity and inclusivity.

Oxford PharmaGenesis COO Richard White said, “News reports over the past year have sharply illustrated how COVID-19 has disproportionately affected people from minority communities. Greater patient diversity will not only help medical researchers to tackle diseases that could affect anyone, but will also help to build trust in treatments. We are proud to work with CISCRP – a leader in patient engagement – on this essential awareness-raising campaign.”

The Spring 2021 campaign aims to reach millions of people through print and digital media, featuring in five US newspapers and on four news websites. It will include a full-page educational spread with sponsored editorial and visual content, alongside a full-page colour advertisement to promote diversity in clinical trials.

Please help us to share this important message, to improve patient diversity and minority representation in clinical trials and help more people to benefit from treatments.